AbbVie picks Singapore for a $320M production facility

Singapore has become a biopharma manufacturing hub, drawing the likes of Novartis ($NVS), GlaxoSmithKline ($GSK) and Amgen ($AMGN). Even Russia's Pharmstandard has an API facility there. Now AbbVie ($ABBV) will join the group. The maker of Humira, the best-selling drug in the world, said Wednesday that it will invest $320 million to build its first facility in Asia. The plant will be designed for both small-molecule production and biologic active ingredients for AbbVie's oncology and immunology pipeline. Story

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.